ArticleBritish journal of pharmacology2000
Ecto-nucleotide pyrophosphatase modulates the purinoceptor-mediated signal transduction and is inhibited by purinoceptor antagonists.
Article in British journal of pharmacology, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 56 citations in OpenAlex.
- ncRNA-mediated low expression of P2RY14 correlates with poor prognosis and tumor immune infiltration in ovarian carcinoma.Annals of translational medicine · 2023Article
- Regulation of coenzyme A levels by degradation: the 'Ins and Outs'.Progress in lipid research · 2020Review
- ENPP1, an Old Enzyme with New Functions, and Small Molecule Inhibitors-A STING in the Tale of ENPP1.Molecules (Basel, Switzerland) · 2019Review
- Identification of adenine-N9-(methoxy)ethyl-β-bisphosphonate as NPP1 inhibitor attenuates NPPase activity in human osteoarthritic chondrocytes.Purinergic signalling · 2019Article
- Dual effects of human neutrophil peptides in a mouse model of pneumonia and ventilator-induced lung injury.Respiratory research · 2018Article
- Review
- Extracellular 4'-phosphopantetheine is a source for intracellular coenzyme A synthesis.Nature chemical biology · 2015Article
- Purinergic signalling and cancer.Purinergic signalling · 2013Review
- Pathophysiology of astroglial purinergic signalling.Purinergic signalling · 2012Review
- Cellular function and molecular structure of ecto-nucleotidases.Purinergic signalling · 2012Review
- Characterization of monoclonal antibodies to the plasma cell alloantigen ENPP1.Hybridoma (2005) · 2011Article
- P2X(1) receptor blockade inhibits whole kidney autoregulation of renal blood flow in vivo.American journal of physiology. Renal physiology · 2010Article
- 2-MeS-beta,gamma-CCl2-ATP is a potent agent for reducing intraocular pressure.Journal of medicinal chemistry · 2010Article
- Kinetic analysis of substrate utilization by native and TNAP-, NPP1-, or PHOSPHO1-deficient matrix vesicles.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2010Article
- Ectonucleotidases in the kidney.Purinergic signalling · 2009Article
- Identification of hydrolytically stable and selective P2Y(1) receptor agonists.European journal of medicinal chemistry · 2009Article
- Biochemical characterization of ecto-nucleotide pyrophosphatase/phosphodiesterase (E-NPP, E.C. 3.1.4.1) from rat heart left ventricle.Molecular and cellular biochemistry · 2007Article
- Specificity of the ecto-ATPase inhibitor ARL 67156 on human and mouse ectonucleotidases.British journal of pharmacology · 2007Article
- Integration of P2Y receptor-activated signal transduction pathways in G protein-dependent signalling networks.Purinergic signalling · 2006Article
- Modulation of purinergic signaling by NPP-type ectophosphodiesterases.Purinergic signalling · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
1. The effect of ecto-nucleotide pyrophosphatase (ecto-NPPase; EC 3.6.1. 9) on the ATP- and ADP-mediated receptor activation was studied in rat C6 glioma cells. The P2-purinoceptor antagonists pyridoxalphosphate-6-azophenyl-2',4'-disulphonic acid (PPADS) and reactive blue (RB2) are potent inhibitors (IC(50)=12+/-3 microM) of the latter enzyme. 4,4'-diisothiocyanatostilbene-2,2' disulfonic acid (DIDS), 5'-phosphoadenosine 3'-phosphate (PAP) and suramin were less potent inhibitors with an IC(50) of 22+/-4, 36+/-7 and 72+/-11 microM respectively. 2. P1-purinoceptor antagonists CGS 15943, cyclo-pentyl theophylline (CTP) and theophylline did not affect the activity of the ecto-NPPase. 3. ATP- and ADP-mediated P2Y(1)-like receptor activation inhibited the (-)-isoproterenol-induced increase of intracellular cyclic AMP concentration. PPADS, an ineffective P2Y-antagonist in C6, potentiated the ATP and ADP effect approximately 3 fold due to inhibition of nucleotide hydrolysis by the ecto-NPPase. 4. We conclude that ecto-NPPase has a modulator effect on purinoceptor-mediated signalling in C6 glioma cell cultures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.